Seneb BioSciences

Seneb BioSciences is a private U.S. biopharmaceutical company developing glycolipid-based therapeutics for neurological and other diseases, with a particular emphasis on orphan and neurodegenerative disorders. The company appears to center its R&D on synthetic gangliosides and related glycolipid analogs designed to improve solubility, brain penetration, and scalability of manufacture. Publicly visible non-dilutive funding and patent activity indicate programs in Batten disease, Huntington's disease, Parkinson's disease, and GM1-related deficiency disorders, all of which appear to remain at preclinical or discovery-stage development. Seneb also has described contract research capabilities spanning production, process development, and analytical testing for proteins, peptides, and small molecules. Its technology base includes proprietary glycolipid synthesis and manufacturing methods intended to enable scalable production of complex gangliosides.